Abstract
Type 2 diabetes remains an escalating world-wide problem, despite a range of treatments. The revelation that insulin secretion is under the control of a gut hormone, glucagon-like peptide 1 (GLP-1), led to a new paradigm in the management of type 2 diabetes. Liraglutide is a long acting GLP-1 receptor agonist used in the treatment of type 2 diabetes. The review considers the clinical trials with liraglutide. There are many comparator trials between liraglutide and other medicines for the treatment of type 2 diabetes, and these trials have shown that liraglutide lowers HbA1c and body weight, and is well tolerated. A large cardiovascular safety trial with liraglutide is presently being undertaken. After 10 years of clinical trials with liraglutide, we do not know whether liraglutide has cardiovascular safety in subjects with type 2 diabetes and high cardiovascular risk. Although this is not a requirement for registration by the Food and Drug Administration (FDA), in my opinion, they should reconsider this. We also do not presently know whether liraglutide has any beneficial effects on clinical cardiovascular outcomes.
Keywords: Clinical outcomes, clinical trials, comparator trials, liraglutide, surrogate endpoints, type 2 diabetes.
Reviews on Recent Clinical Trials
Title:After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?
Volume: 10 Issue: 1
Author(s): Sheila A. Doggrell
Affiliation:
Keywords: Clinical outcomes, clinical trials, comparator trials, liraglutide, surrogate endpoints, type 2 diabetes.
Abstract: Type 2 diabetes remains an escalating world-wide problem, despite a range of treatments. The revelation that insulin secretion is under the control of a gut hormone, glucagon-like peptide 1 (GLP-1), led to a new paradigm in the management of type 2 diabetes. Liraglutide is a long acting GLP-1 receptor agonist used in the treatment of type 2 diabetes. The review considers the clinical trials with liraglutide. There are many comparator trials between liraglutide and other medicines for the treatment of type 2 diabetes, and these trials have shown that liraglutide lowers HbA1c and body weight, and is well tolerated. A large cardiovascular safety trial with liraglutide is presently being undertaken. After 10 years of clinical trials with liraglutide, we do not know whether liraglutide has cardiovascular safety in subjects with type 2 diabetes and high cardiovascular risk. Although this is not a requirement for registration by the Food and Drug Administration (FDA), in my opinion, they should reconsider this. We also do not presently know whether liraglutide has any beneficial effects on clinical cardiovascular outcomes.
Export Options
About this article
Cite this article as:
Doggrell A. Sheila, After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?, Reviews on Recent Clinical Trials 2015; 10 (1) . https://dx.doi.org/10.2174/1574887110666150417164603
DOI https://dx.doi.org/10.2174/1574887110666150417164603 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting AMPK Signaling in the Liver: Implications for Obesity and
Type 2 Diabetes Mellitus
Current Drug Targets Docosahexaenoic Acid Ester of Phloridzin Reduces Inflammation and Insulin Resistance <i>via</i> AMPK
Current Pharmaceutical Design Therapeutic Nanosystems for Oral Administration of Insulin
Current Pharmaceutical Biotechnology Identification of an Extracellular Antifungal Protein from the Endophytic Fungus Colletotrichum sp. DM06
Protein & Peptide Letters Recent Medicinal Chemistry Studies for Multitarget Agents-Part II
Current Drug Targets Determination of Epsilon Aminocaproic Acid Based on Charge Transfer Complexation with p-Nitrophenlol by Spectrophotometry
Current Pharmaceutical Analysis Development and Validation of Teneligliptin Stereoisomers by HPLC Using Cellulose Based Immobilized Polysaccharide Chiral Stationary Phase
Current Pharmaceutical Analysis NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases
Current Drug Targets Statins in Diabetes Mellitus
Current Pharmaceutical Design Implications of Dietary Leucine on Muscle mTOR Gene Expression and Redox Status in Rats Following High Intensity Effort
Current Nutrition & Food Science A Direct Correlation between Red Blood Cell Indices and Cognitive Impairment After Aneurysmal Subarachnoid Hemorrhage (aSAH)
Current Neurovascular Research The Role of Extracellular Adenosine in Chemical Neurotransmission in the Hippocampus and Basal Ganglia: Pharmacological and Clinical Aspects
Current Topics in Medicinal Chemistry Sorghum (Sorghum bicolor) Extract Affects Plasma Lipid Metabolism and Hepatic Macrophage Infiltration in Diabetic Rats
Current Nutrition & Food Science Integration of Internet of Things with Quantum Dots: A State-of-the-art of Medicine
Current Pharmaceutical Design Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Efficacy of Argane Oil on Metabolic Syndrome in a Moroccan Knee Osteoarthritis Population
Current Rheumatology Reviews PTEN, Insulin Resistance and Cancer
Current Pharmaceutical Design Physiologically Based Pharmacokinetic Models: Integration of In Silico Approaches with Micro Cell Culture Analogues
Current Drug Metabolism Chemical Penetration Enhancers for Transdermal Drug Delivery- Success and Challenges
Current Drug Delivery Atherosclerotic Renal Artery Stenosis: An Update on Diagnosis and Management
Current Vascular Pharmacology